Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (188)	4/16/2005 6:43:38 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

Just seems odd to give minus 9 million to this. Obviously, alot of PR is fluff, I simply pasted the whole list--but there is a smattering of substance. Gene Logic has 50 or more patents too, the list seems to have gone missing since their website was redesigned, it is somewhere. 03/17/2005 Gene Logic Provides Financial Guidance and Plan for Company Growth; CEO Details Potential for Drug Repositioning and Selection Business and Targets for Assessing Progress 03/10/2005 Gene Logic Releases Improved Software for Discovering Drug Targets and Assessing Safety of Compounds 03/10/2005 Gene Logic to Announce 2005 Financial Guidance and Discuss Details of Strategic Direction on March 17, 2005 03/07/2005 Gene Logic Inc. Recruits Former Life Technologies and Invitrogen Executive as General Manager for Gene Logic's Preclinical Contract Research Services 03/07/2005 Gene Logic Offers Microarray Data Generation and Analysis Services to Meet Pharmaceutical and Research Customer Needs 02/24/2005 Gene Logic Sees Growing Trend from Pharma Industry for Safety Testing 02/22/2005 Gene Logic Launches ToxShield Suite to Enable Customers to Conduct Predictive Toxicogenomic Characterizations of Drug Compounds In-House 02/18/2005 Gene Logic Reports Fourth Quarter and Full Year 2004 Financial Results 01/31/2005 Gene Logic to Announce Fourth Quarter and Full Year 2004 Financial Results on February 18, 2005 12/01/2004 Frank L. Douglas, Former Aventis Executive, Joins Gene Logic Inc. Board of Directors 11/16/2004 Gene Logic K.K. Officially Opens Office in Japan; Gene Logic Solidifies Local Presence to Meet the Needs of Japanese Pharmaceutical Customers 11/10/2004 Gene Logic Inc. Elects J. Stark Thompson Non-Executive Chairman of the Board; Company Moves to Reflect Highest Standards of Corporate Governance 10/22/2004 Gene Logic Reports Third Quarter 2004 Results 10/08/2004 National Institute on Drug Abuse Awards Gene Logic Multi-Year Contract for Preclinical Studies; Contract Arrangement Potentially Valued at $6.0 Million Over 4 Years 10/06/2004 Gene Logic to Announce Third Quarter 2004 Results on October 22, 2004 08/18/2004 Gene Logic Expands International Operations; Establishes Staff in UK and Germany; Forms Gene Logic K.K. to Serve Japanese Market 07/28/2004 Organon Selects Gene Logic's Comprehensive Toxicogenomics Services 07/23/2004 Gene Logic Conference Call at 9:00 A.M. Today to Discuss Q2 Results Announcement on Technology Program from Millennium Pharmaceuticals 07/23/2004 Gene Logic Acquires Technology Program From Millennium Pharmaceuticals; Launches Business to Identify New Indications for Drugs; Millennium Becomes First Customer for New Service 12/22/2003 GlaxoSmithKline Renews BioExpress Subscription with Gene Logic; Continues Use of Comprehensive Gene Expression Tool Begun in Late 2001 12/16/2003 Registration of Certain Gene Logic Shares on Form S-3 Declared Effective 12/12/2003 Registration of Gene Logic Shares Issued in TherImmune Acquisition To Become Effective 11/12/2003 Gene Logic Rebalances Workforce Following Acquisition; Directing Additional Resources to Contract Study Services, Marketing and Sales 11/11/2003 Webcast Alert: Gene Logic Presentation at Informed Investors Biotechnology/Healthcare Stocks Forum to be Webcast on Thursday, November 13, 2003, 9 am ET 11/10/2003 Gene Logic To Build Custom Equine Gene Expression Database for Genetraks 10/24/2003 Aventis Renews Business with Gene Logic 10/24/2003 Gene Logic Reports Third Quarter 2003 Results; Revenue Increases 25% 10/06/2003 Gene Logic to Host Conference Call and Webcast Announcing Third Quarter 2003 Results 10/01/2003 Gene Logic Announces Post-Acquisition Integration and Market Alignment Strategy; Steve Trevisan Steps Down as Executive Vice President and Director 09/23/2003 Gene Logic Updates Outlook for 2003 12/12/2002 Roche Signs Agreement for Customized GeneExpress Product from Gene Logic 10/28/2002 Gene Logic Reports Third Quarter 2002 Results 10/07/2002 IDEC Pharmaceuticals Extends Subscription to Gene Logic's GeneExpress Oncology DataSuite 10/03/2002 Fujisawa Pharmaceutical Subscribes to Gene Logic's GeneExpress Atlas DataSuite 10/01/2002 Gene Logic to Host Conference Call and Webcast Announcing Third Quarter 2002 Results 09/04/2002 Mitsubishi Pharma Subscribes to Gene Logic's BioExpress Database 08/05/2002 Gene Logic Expands ToxExpress Product Offering: Launches ToxSuites and ToxScreen Reports 07/29/2002 Gene Logic Reports Second Quarter 2002 Results 07/08/2002 Gene Logic To Host Conference Call and Webcast to Announce Second Quarter 2002 Results 06/28/2002 Gene Logic Signs GeneExpress CustomSuite Agreement with Schering-Plough Research Institute 06/09/2002 Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite 04/29/2002 Gene Logic Reports First Quarter 2002 Results 04/08/2002 Gene Logic To Host Conference Call and Webcast to Announce First Quarter 2002 Results 03/27/2002 Takeda Chemical Industries, Ltd. Subscribes to Gene Logic's GeneExpress 12/31/2001 Gene Logic Extends Market Reach with Launch of GeneExpress Reports and Signs Five Biotechnology Customers 12/21/2001 Gene Logic Announces Expanded Business Relationship with Pfizer 12/13/2001 Gene Logic Establishes Genomic Database Agreement with Aventis Pharmaceuticals 12/10/2001 GlaxoSmithKline Subscribes to Gene Logic's GeneExpress Suite of Gene Expression Information Products; Agreement to Include Access to BioExpress Module and In-House Data Integration 11/27/2001 Gene Logic to Expand GeneExpress Suite Through Exclusive License to Protein Pathways from BioCarta Inc. 11/16/2001 Gene Logic Reports 2002 Financial Guidance; Projected 52% Y/Y Revenue Growth and Significant Y/Y Reduction in Losses 11/13/2001 Gene Logic to Host Conference Call and Webcast to Announce 2002 Financial Guidance 10/29/2001 Gene Logic Reports Third Quarter 2001 Results; --Revenues Increase 114% to Record Level, Loss Narrows, and GeneExpress Suite Business Growth Highlight Quarter-- 10/10/2001 Gene Logic CEO to Present at UBS Warburg Global Life Sciences Conference 10/04/2001 Gene Logic Announces Subscription Extension with Pfizer 10/01/2001 Gene Logic to Host Conference Call and Webcast to Announce Third Quarter 2001 Results 12/22/2000 Gene Logic Extends Collaboration with Procter & Gamble; P&G to subscribe to GeneExpress DataSuite 12/21/2000 Boehringer Ingelheim Subscribes to Gene Logic's GeneExpress Database 12/21/2000 Gene Logic and Biogen Sign Custom Database Agreement 12/21/2000 Gene Logic Signs Organon to GeneExpress Subscription And Custom Discovery Agreement 12/04/2000 Gene Logic Signs LG Chemical to GeneExpress Subscription And Custom Discovery Partnership 10/30/2000 Gene Logic Reports Third Quarter 2000 Results -- Revenues Increased 25% over Prior Year's Third Quarter -- 10/03/2000 Gene Logic: Q3 2000 Conference Call Invitation 10/02/2000 Gene Logic Signs UCB Pharma to GeneExpress(TM) Subscription And Announces Expansion of Custom Discovery Partnership 09/26/2000 Gene Logic and Amersham Pharmacia Biotech K.K. Announce Japanese Business Development Collaboration 08/10/2000 Genomics Collaborative Enters Genomics Agreement with Gene Logic 07/27/2000 Gene Logic Reports Second Quarter 2000 Results - Revenues Increased 26% Over Prior Year's Second Quarter 06/30/2000 Gene Logic Signs Psychiatric Genomics to GeneExpress(TM) Subscription 06/30/2000 Gene Logic Signs Genaissance Pharmaceuticals to GeneExpress(TM) Subscription and Enters Collaboration Agreement 12/29/1999 Gene Logic Announces Issuance of a U.S. Patent Covering Key Gene Expression Technology 12/15/1999 Gene Logic Discovers Genes for Renal Disease 12/07/1999 Gene Logic Expects Patent Suit Will Have Little Impact on Its Business 12/03/1999 Gene Logic Outlines Growth Strategy at Robertson Stephens Medical Conference 12/02/1999 Gene Logic and Fujisawa Pharmaceutical Sign Collaborative Discovery Research Alliance; Companies to Identify Gene Expression Profiles for Diabetes Therapeutics 11/04/1999 Gene Logic Reports Third-Quarter 1999 Results 11/03/1999 Gene Logic Names Philip L. Rohrer Jr. Chief Financial Officer 10/06/1999 Gene Logic Identifies 4,300 Genes with Potential Commercial Utility 09/27/1999 Gene Logic and UCB Research Sign Gene Expression Database Agreement 08/05/1999 Gene Logic Reports Second-Quarter 1999 Results 08/03/1999 2Q 1999 Conference Call Invitation 05/06/1999 Gene Logic Reports First-Quarter 1999 Results 03/31/1999 Gene Logic Reports Final Fourth-Quarter and Year-End 1998 Results 12/14/1998 Gene Logic, Procter & Gamble Pharmaceuticals Expand Drug Discovery Collaboration 12/10/1998 Gene Logic Receives Patent on New Chip for Studying DNA, Other Molecules 11/23/1998 Rhone-Poulenc Rorer Gencell and Gene Logic Expand Pharmacogenomics Collaboration 11/23/1998 Gene Logic's CEO Interviewed on the Web 11/13/1998 Gene Logic Reports Third-Quarter Results 10/28/1998 Gene Logic Names Jim Veitch Vice President, Business Development, of Data Logic Division 10/14/1998 Gene Logic Promotes Victor M. Markowitz, Expands Data Logic Division 10/05/1998 Gene Logic Receives Patent Covering Critical Genomics Technology 09/28/1998 Gene Logic Completes Aquisition of Oncormed 09/10/1998 Gene Logic Names Stephen Push Vice President,Corporate Communications 08/07/1998 Gene Logic Reports Second Quarter Results 07/07/1998 Gene Logic to acquire Oncormed 07/07/1998 Additional Details of Oncormed Aquisition 07/01/1998 Gene Logic and Hoechst Schering AgrEvo Enter Alliance 12/23/1997 Gene Logic Announce Excercise of Over-Allotment Option 11/21/1997 Gene Logic inc. Raises $24 Million in Initial Public Offering 10/07/1997 Gene Logic inc. Files Registration Statement for Initial Public Offering 10/06/1997 Dr. Victor Markowitz to Head the Newly-established Gene Logic Bioinformatics Systems Division 09/17/1997 Dr. Greg Lennon Joins Gene Logic as Vice President, Genomics 09/09/1997 Gene Logic Enters Genomics Alliance with Japan Tobacco for Drug Discovery in Renal Disease and Other Indications 07/16/1997 Gene Logic Raises $20 Million In Private Financing 07/07/1997 Gene Logic Inc Promotes Christopher T. Dunne, CPA to Director, Finance & Administration 06/13/1997 Gene Logic Enters Alliance with Procter & Gamble for Drug Target Discovery in Heart Failure 03/24/1997 Gene Logic and Molecular Geriatrics Corporation Announce Alzheimer’s Disease Gene Discovery Collaboration 03/21/1997 Gene Logic Inc Announces Senior Appointments in Bioinformatics 01/28/1997 Gene Logic Inc. Appoints Dan Passeri as Senior Vice President, Technology and Program Management